Mursla is Cambridge-based startup developing a novel tech platform to trace tumours early in the blood via the discovery and quantification of cancer-specific exosome subpopulations.

Operator of a cancer liquid biopsy company intended to trace tumors in the blood via cancer-specific exosomes. The company's novel technology platform leverages proprietary nanostructures and simplifies the whole cycle of cancer management, enabling researchers to improve cancer detection, thereby permitting more lives to be saved.